ES2138565B1 - Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. - Google Patents

Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.

Info

Publication number
ES2138565B1
ES2138565B1 ES009801003A ES9801003A ES2138565B1 ES 2138565 B1 ES2138565 B1 ES 2138565B1 ES 009801003 A ES009801003 A ES 009801003A ES 9801003 A ES9801003 A ES 9801003A ES 2138565 B1 ES2138565 B1 ES 2138565B1
Authority
ES
Spain
Prior art keywords
livers
treatment
viral
subtype
ifna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES009801003A
Other languages
English (en)
Other versions
ES2138565A1 (es
Inventor
Valtuena Jesus Prieto
Murillo Pilar Civeira
Leoz Esther Larrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009801003A priority Critical patent/ES2138565B1/es
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to BR9911774-6A priority patent/BR9911774A/pt
Priority to EP99919282A priority patent/EP1077068B9/en
Priority to CNB998078662A priority patent/CN1173738C/zh
Priority to JP2000547994A priority patent/JP2002514606A/ja
Priority to PT99919282T priority patent/PT1077068E/pt
Priority to DE69901099T priority patent/DE69901099T4/de
Priority to AU37111/99A priority patent/AU753463B2/en
Priority to ES99919282T priority patent/ES2174604T3/es
Priority to SI9930043T priority patent/SI1077068T1/xx
Priority to RU2000131172/14A priority patent/RU2209079C2/ru
Priority to DE69901099A priority patent/DE69901099D1/de
Priority to PCT/ES1999/000134 priority patent/WO1999058143A1/es
Priority to SE99919282T priority patent/SE1077068T5/xx
Priority to AT99919282T priority patent/ATE214941T1/de
Priority to CA2335645A priority patent/CA2335645C/en
Priority to DK99919282T priority patent/DK1077068T5/da
Priority to US09/674,445 priority patent/US6995133B1/en
Publication of ES2138565A1 publication Critical patent/ES2138565A1/es
Application granted granted Critical
Publication of ES2138565B1 publication Critical patent/ES2138565B1/es
Priority to US11/212,126 priority patent/US7501392B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso del interferon alfa-5 en el tratamiento de las hepatopatías virales. La invención describe la síntesis disminuida de IFNa-5 en hígados de pacientes con hepatitis C, frente a hígados de controles sanos. El subtipo de IFN expresado en dichos hígados sanos, correspondió únicamente al subtipo alfa-5, frente a los diferentes subtipos expresados en hígados enfermos. En SEQ ID NO:1 se muestra la secuencia parcial de cADN correspondiente a IFNa 5. Estas diferencias significativas entre los patrones de expresión de unos hígados y otros ponen de manifiesto la importancia del uso de este subtipo de interferon en la fabricación de composiciones útiles en el tratamiento de hepatopatías de origen viral. En la invención se describe pormenorizadamente esta utilización bajo diferentes formas y procedimientos, incluyendo aquellos que utilizan la producción de proteínas recombinantes, a partir de secuencias tipo SEQ ID NO:1.
ES009801003A 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es. Expired - Lifetime ES2138565B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES009801003A ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
DE69901099A DE69901099D1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
CNB998078662A CN1173738C (zh) 1998-05-13 1999-05-13 干扰素α5在制备治疗病毒性肝脏疾病的组合物中的应用
JP2000547994A JP2002514606A (ja) 1998-05-13 1999-05-13 ウィルス性肝疾患の治療へのインターフェロンα５の使用
PT99919282T PT1077068E (pt) 1998-05-13 1999-05-13 Utilizacao do interferao alfa 5 no tratamento de hepatopatias virais
DE69901099T DE69901099T4 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
AU37111/99A AU753463B2 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
SE99919282T SE1077068T5 (sv) 1998-05-13 1999-05-13 Anvaendning av interferon-alfa-5 vid behandling av virus-hepatopatier
EP99919282A EP1077068B9 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
RU2000131172/14A RU2209079C2 (ru) 1998-05-13 1999-05-13 Применение интерферона-альфа 5 в лечении вирусных заболеваний печени
BR9911774-6A BR9911774A (pt) 1998-05-13 1999-05-13 Uso de interferon alfa 5 no tratamento das hepatopatias virais
SI9930043T SI1077068T1 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
ES99919282T ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.
AT99919282T ATE214941T1 (de) 1998-05-13 1999-05-13 Verwendung von interferon alpha 5 in der behandlung viraler hepatopathien
CA2335645A CA2335645C (en) 1998-05-13 1999-05-13 Use of interferon alpha 5 in the treatment of viral liver diseases
DK99919282T DK1077068T5 (da) 1998-05-13 1999-05-13 Anvendelse af interferon alfa 5 i behandlingen af virale hepatopatier
US09/674,445 US6995133B1 (en) 1998-05-13 1999-05-13 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
PCT/ES1999/000134 WO1999058143A1 (es) 1998-05-13 1999-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias virales
US11/212,126 US7501392B2 (en) 1998-05-13 2005-08-25 Method of treatment of viral hepatitis C with interferon alpha 5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801003A ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.

Publications (2)

Publication Number Publication Date
ES2138565A1 ES2138565A1 (es) 2000-01-01
ES2138565B1 true ES2138565B1 (es) 2000-08-16

Family

ID=8303773

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801003A Expired - Lifetime ES2138565B1 (es) 1998-05-13 1998-05-13 Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
ES99919282T Expired - Lifetime ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99919282T Expired - Lifetime ES2174604T3 (es) 1998-05-13 1999-05-13 Utilizacion de interferon alfa 5 en el tratamiento de las hepatopatias de origen viral.

Country Status (15)

Country Link
US (2) US6995133B1 (es)
EP (1) EP1077068B9 (es)
JP (1) JP2002514606A (es)
CN (1) CN1173738C (es)
AT (1) ATE214941T1 (es)
AU (1) AU753463B2 (es)
BR (1) BR9911774A (es)
CA (1) CA2335645C (es)
DE (2) DE69901099T4 (es)
DK (1) DK1077068T5 (es)
ES (2) ES2138565B1 (es)
PT (1) PT1077068E (es)
RU (1) RU2209079C2 (es)
SE (1) SE1077068T5 (es)
WO (1) WO1999058143A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110179530A1 (en) * 2001-01-23 2011-07-21 University Of Central Florida Research Foundation, Inc. Pharmaceutical Proteins, Human Therapeutics, Human Serum Albumin Insulin, Native Cholera Toxin B Subunit on Transgenic Plastids
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.
CN102869767B (zh) * 2010-02-01 2016-03-09 迪格纳生物技术公司 干扰素α5的制备方法
BR112013032188A2 (pt) * 2011-06-23 2016-12-20 Digna Biotech Sl composição, produto e método para tratar pacientes com hepatite c crônica
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973479A (en) * 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
SG47766A1 (en) * 1991-03-12 1998-04-17 Biogen Inc CD2-binding domain of lymphocyte function associated antigen 3
RU2052264C1 (ru) * 1993-07-19 1996-01-20 Товарищество с ограниченной ответственностью "Полисан" Лекарственное средство для лечения вирусных заболеваний у животных
PT741577E (pt) * 1994-03-07 2003-03-31 Imperial College Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Also Published As

Publication number Publication date
CA2335645A1 (en) 1999-11-18
WO1999058143A1 (es) 1999-11-18
ATE214941T1 (de) 2002-04-15
AU753463B2 (en) 2002-10-17
AU3711199A (en) 1999-11-29
US6995133B1 (en) 2006-02-07
DE69901099T4 (de) 2003-03-13
ES2138565A1 (es) 2000-01-01
RU2209079C2 (ru) 2003-07-27
DK1077068T5 (da) 2002-10-14
EP1077068B1 (en) 2002-03-27
ES2174604T3 (es) 2002-11-01
DE69901099T2 (de) 2002-11-07
US20060188477A1 (en) 2006-08-24
SE1077068T3 (sv) 2002-07-02
JP2002514606A (ja) 2002-05-21
SE1077068T5 (sv) 2003-03-04
WO1999058143A9 (es) 2002-08-22
DK1077068T3 (da) 2002-07-22
US7501392B2 (en) 2009-03-10
EP1077068A1 (en) 2001-02-21
DE69901099D1 (de) 2002-05-02
CA2335645C (en) 2011-01-04
EP1077068B9 (en) 2002-10-02
CN1173738C (zh) 2004-11-03
CN1307482A (zh) 2001-08-08
BR9911774A (pt) 2001-02-06
PT1077068E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
BR9912448A (pt) Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
CY1106558T1 (el) Glp-2 σκευασματα
ATE209216T1 (de) Cyclosporin-derivate mit anti-hiv-wirkung
DE69509628D1 (de) N-terminal chemisch modifizierte protein-zusammensetzungen und methoden
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
NO20023852L (no) Nukleosidanaloger med karboksamidin-modifisert bisyklisk base
EP1548028A4 (en) SUBSTITUTED WT1 PEPTIDES
AR013497A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
DE602004029038D1 (de) Hip/pap polypeptide zusammensetzung zur verwendung zur leberregeneration und zur vorbeugung von leberinsuffizienz
ES2138565B1 (es) Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
DE69133349D1 (de) Ein nicht-mitogener kompetitiver hgf-antagonist
ATE403726T1 (de) Cytokin-proteinfamilie
UY27827A1 (es) Composiciones y su uso terapeutico
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
HRP20040663B1 (hr) Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora
AR038900A1 (es) Moleculas similares al interferon beta para el tratamiento del derrame cerebral
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
ATE371737T1 (de) Proteaseresistente flint-analoge
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
BRPI0406985A (pt) Terapia de combinação de hcv
ES2023746A6 (es) Procedimiento de preparacion de peptidos de serina-acido aspartico- lisina

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000101

Kind code of ref document: A1

Effective date: 20000101